FibroBiologics
FBLG | NASDAQ
$0.90
-$0.03 (-2.92%)
At close: Nov 16, 2026, 4:00 PM ET
$0.90
$0.00 (+0.38%)
After-hours:
Nov 16, 2026, 7:30 PM ET
FibroBiologics Company Profile
Company profile explainedCompany Profile
FibroBiologics, Inc. operates as a clinical-stage biopharmaceutical firm, advancing therapies derived from fibroblasts toward commercialization within the United States. The company's pipeline includes CybroCell, currently being developed to address degenerative disc disease; CYMS101, targeting multiple sclerosis; and CYWC628 for wound repair. Further demonstrating its broad scope, early-stage investigations are underway for CYTER915, aimed at restoring or enhancing thymus and/or spleen function; CYPS317, for psoriasis; and TCB190, designed to combat specific cancers. FibroBiologics was founded in 2021 and is situated in Houston, Texas.
Key Executives
| Name | Position |
|---|---|
| Peter O'Heeron | Founder, Chairperson & Chief Executive Officer |
| Jason D. Davis | Chief Financial Officer |
| Hamid Khoja | Chief Scientific Officer |
| Ruben A. Garcia | General Counsel |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 19, 2026 | EFFECT | Filing |
| Oct 19, 2026 | EFFECT | Filing |
| Oct 13, 2026 | POS AM | Filing |
| Oct 13, 2026 | POS AM | Filing |
| Oct 13, 2026 | D | Filing |
| Oct 08, 2026 | 8-K | Current Report |
| Sep 18, 2026 | 8-K | Current Report |
| Sep 17, 2026 | SC 13D | Filing |
| Sep 15, 2026 | 4 | Filing |
| Sep 16, 2026 | D | Filing |
FibroBiologics
| Country | United States |
| IPO Date | Feb 1, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 15 |
| CEO | Peter O'Heeron |
Contact Details
455 East Medical Center Boulevard Houston,
Texas 77598 United States
Stock Details
| Ticker Symbol | FBLG |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001958777 |
| CUSIP Number | 31573L204 |
| ISIN Number | US31573L2043 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove FBLG